Literature DB >> 16477891

Diagnosis and treatment of community-acquired pneumonia.

M Nawal Lutfiyya1, Eric Henley, Linda F Chang, Stephanie Wessel Reyburn.   

Abstract

Patients with community-acquired pneumonia often present with cough, fever, chills, fatigue, dyspnea, rigors, and pleuritic chest pain. When a patient presents with suspected community-acquired pneumonia, the physician should first assess the need for hospitalization using a mortality prediction tool, such as the Pneumonia Severity Index, combined with clinical judgment. Consensus guidelines from several organizations recommend empiric therapy with macrolides, fluoroquinolones, or doxycycline. Patients who are hospitalized should be switched from parenteral antibiotics to oral antibiotics after their symptoms improve, they are afebrile, and they are able to tolerate oral medications. Clinical pathways are important tools to improve care and maximize cost-effectiveness in hospitalized patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16477891

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  25 in total

1.  Pneumonia identification using statistical feature selection.

Authors:  Cosmin Adrian Bejan; Fei Xia; Lucy Vanderwende; Mark M Wurfel; Meliha Yetisgen-Yildiz
Journal:  J Am Med Inform Assoc       Date:  2012-04-26       Impact factor: 4.497

2.  Role of Semi-quantitative Serum Procalcitonin in Assessing Prognosis of Community Acquired Bacterial Pneumonia Compared to PORT PSI, CURB-65 and CRB-65.

Authors:  Lalita Fernandes; Akashdeep Singh Arora; Anthony Menezes Mesquita
Journal:  J Clin Diagn Res       Date:  2015-07-01

Review 3.  Pediatric lung ultrasound - pros and potentials.

Authors:  Jovan Lovrenski
Journal:  Pediatr Radiol       Date:  2020-02-17

Review 4.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Assessing pneumonia identification from time-ordered narrative reports.

Authors:  Cosmin A Bejan; Lucy Vanderwende; Mark M Wurfel; Meliha Yetisgen-Yildiz
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

6.  Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit.

Authors:  Cornelis P C de Jager; Paul T L van Wijk; Rejiv B Mathoera; Jacqueline de Jongh-Leuvenink; Tom van der Poll; Peter C Wever
Journal:  Crit Care       Date:  2010-10-29       Impact factor: 9.097

7.  Elevated plasma stromal-cell-derived factor-1 protein levels correlate with severity in patients with community-acquired pneumonia.

Authors:  Ping-Kun Tsai; Ming-Ju Hsieh; Hsiang-Ling Wang; Ming-Chih Chou; Shun-Fa Yang; Chao-Bin Yeh
Journal:  Dis Markers       Date:  2014-10-13       Impact factor: 3.434

8.  Consolidated lung on contrast-enhanced chest CT: the use of spectral-detector computed tomography parameters in differentiating atelectasis and pneumonia.

Authors:  Philip Konietzke; Hauke H Steentoft; Willi L Wagner; Jonas Albers; Christian Dullin; Stephan Skornitzke; Wolfram Stiller; Tim F Weber; Hans-Ulrich Kauczor; Mark O Wielpütz
Journal:  Heliyon       Date:  2021-05-26

9.  The incidence and aetiology of hospitalised community-acquired pneumonia among Vietnamese adults: a prospective surveillance in Central Vietnam.

Authors:  Kensuke Takahashi; Motoi Suzuki; Le Nhat Minh; Nguyen Hien Anh; Luu Thi Minh Huong; Tran Vo Vinh Son; Phan The Long; Nguyen Thi Thuy Ai; Le Huu Tho; Konosuke Morimoto; Paul E Kilgore; Dang Duc Anh; Koya Ariyoshi; Lay Myint Yoshida
Journal:  BMC Infect Dis       Date:  2013-07-01       Impact factor: 3.090

10.  Urine real-time polymerase chain reaction detection for children virus pneumonia with acute human cytomegalovirus infection.

Authors:  Zhidai Liu; Penghui Zhang; Shi Tang; Xiaoyan He; Rong Zhang; Xinbin Wang; Zhaojian Yuan; Junjie Tan; Bin Peng; Enmei Liu; Zhou Fu; Lin Zou
Journal:  BMC Infect Dis       Date:  2014-05-08       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.